Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥4,065 JPY
Change Today +155.00 / 3.96%
Volume 204.0K
4516 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
As of 9:45 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

nippon shinyaku co ltd (4516) Snapshot

Open
¥3,965
Previous Close
¥3,910
Day High
¥4,070
Day Low
¥3,940
52 Week High
03/13/15 - ¥4,790
52 Week Low
07/17/14 - ¥2,755
Market Cap
285.6B
Average Volume 10 Days
264.3K
EPS TTM
¥87.29
Shares Outstanding
70.3M
EX-Date
09/28/15
P/E TM
46.6x
Dividend
¥28.00
Dividend Yield
0.62%
Current Stock Chart for NIPPON SHINYAKU CO LTD (4516)

Related News

No related news articles were found.

nippon shinyaku co ltd (4516) Related Businessweek News

No Related Businessweek News Found

nippon shinyaku co ltd (4516) Details

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs. The company offers drugs for pain, inflammation, and allergies; hematologic malignancies; urological diseases; gastrointestinal disorders; cardiovascular and metabolic diseases; and other diseases. Its products include Tramal for cancer and chronic pain; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid; Livostin for allergic rhinitis and conjunctivitis; Hypen, a non-steroidal anti-inflammatory and analgesic agent; Zalutia for urinary disorder caused by benign prostatic; Cialis for erectile dysfunction; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; Trisenox for relapsed and refractory acute promyelocytic leukemia; and Amnolake for relapsed and refractory acute promyelocytic leukemia. The company’s products also include Gaslon N for gastric ulcer and gastritis; Portolac, an antihyperammonemia agent; Adcirca for pulmonary arterial hypertension; Selectol, a vasodilating beta-1 blocker; Regtect for maintaining alcohol abstinence; Lunabell for dysmenorrhea; and Cephadol for vertigo. The company is also involved in the research and development, and marketing of drugs in the areas of urology, hematology, gynecology, otolaryngology, and orthopedics. In addition, it provides functional foods, including health food ingredients, preservatives/shelf life improvers, protein preparations, and spice and condiments. The company was founded in 1911 and is headquartered in Kyoto, Japan.

Founded in 1911

nippon shinyaku co ltd (4516) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nippon shinyaku co ltd (4516) Key Developments

Nippon Shinyaku Co., Ltd. and Actelion Pharmaceuticals Japan Ltd Launch Opsumit® Tablet 10 mg for the Treatment of Pulmonary Arterial Hypertension

Nippon Shinyaku Co. Ltd. and Actelion Pharmaceuticals Japan Ltd. announced the launch of “Opsumit® Tablet 10 mg” onto the Japanese Market. Opsumit® (Macitentan) Tablet has been developed jointly by Actelion Japan and Nippon Shinyaku. Actelion Japan received marketing approval for Opsumit® for the treatment of pulmonary arterial hypertension in Japan in March 2015. Opsumit® is an endothelin receptor antagonist. In the global Phase III SERAPHIN study, treatment with macitentan 10mg once a day resulted in 45% risk reduction (p<0.0001) of the composite morbidity-mortality endpoint when compared to placebo. Improvements in pulmonary vascular resistance, 6MWD, and WHO functional class were observed in a local clinical study conducted in Japan. PAH treatments currently available in Japan are classified into three different classes of drugs (PDE5 inhibitors, IP receptor agonists, and endothelin receptor antagonists). With the launch of Opsumit®, Nippon Shinyaku will have products of these three classes in its portfolio along with “Adcirca® Tablet 20mg”(launched) and NS-304 (selexipag, under development). Actelion Japan will market and distribute the product in Japan, while Actelion Japan and Nippon Shinyaku will co-promote the product. Nippon Shinyaku is hopeful that the PAH patients and their family will benefit from wider treatment options for their difficult-to-treat disease. Both companies will work together to make Opsumit® available in clinical practice in Japan as soon as possible.

Nippon Shinyaku Co. Ltd. and Pfizer Japan, Inc. Launch Oral Tramadol Sustained Release Tablet "Onetram® Tablet 100 Mg"

Nippon Shinyaku Co. Ltd. and Pfizer Japan Inc. announced that two companies have launched an oral tramadol sustained release tablet "Onetram® tablet 100 mg", for which Nippon Shinyaku obtained manufacturing and marketing authorization in March 2015. Onetram® is a tablet of tramadol hydrochloride, which is the same active ingredient as in "Tramal® Capsule 25 mg, 50 mg and Tramal® OD tablet 25 mg, 50 mg (four times administration per day)" launched by Nippon Shinyaku for the treatment of cancer pain and chronic pain, but applied to a unique sustained release technology owned by Endo Ventures Limited (Headquarters: Dublin, Ireland). The tablet is a once-daily oral formulation which has both fast-acting and long- lasting properties by consisting of an immediate releasing outer layer and a sustained releasing core. Tramadol hydrochloride is a centrally-acting analgesic originally synthesized in Germany, and launched with various formulation forms in more than one hundred countries. As a non-scheduled medicine in Japan, tramadol is prescribed for the treatment of cancer pain and chronic pain for the many patients for whom non-opioid analgesics are not adequate. While all oral formulations of tramadol approved so far in Japan have been immediate releasing medicines, Onetram® is the first controlled release tablet. Compared with the immediate releasing tablets which required several administrations per day, the new formulation should increase medication adherence of patients by providing a stable analgesic effect with a once-daily oral administration. That is a large benefit for patients, who require pain control on a long term basis.

Nippon Shinyaku Co. Ltd. Reports Consolidated Earnings Results for the Year Ended March 31, 2015; Provides Earnings Guidance for the First Half and Full Year of Year Ending March 31, 2016; Declares Dividend for the Full Year Ended March 31, 2015, Payable on June 29, 2015; Provides Dividend Guidance for the Second Quarter and Full Year of Year Ending March 31, 2016

Nippon Shinyaku Co. Ltd. reported consolidated earnings results for the year ended March 31, 2015. For the year, the company reported net sales of ¥79,991 million against ¥76,517 million a year ago. Operating income was ¥8,562 million against ¥8,038 million a year ago. Ordinary income was ¥8,928 million against ¥8,598 million a year ago. Income before income taxes and minority interests was ¥87,928 million against ¥8,598 million a year ago. Net income was ¥5,882 million or ¥87.26 per basic share compared ¥5,750 million or ¥85.25 per basic share reported a year ago. Net cash provided by operating activities were ¥6,113 million against ¥6,015 million a year ago. Purchases of tangible fixed assets were ¥1,156 million against ¥1,121 million reported a year ago. Purchases of intangible assets were ¥109 million against ¥142 million reported a year ago. The company provided earnings guidance for the first half and full year of year ending March 31, 2016. For the half year of fiscal year ending March 31, 2016, the company expects to report net sales of ¥41,000 million, operating income of ¥2,200 million, ordinary income of ¥2,300 million and net income attributable to owners of the parent of ¥1,500 million or ¥22.26 per basic share. For the year ending March 31, 2016, the company expects to report net sales of ¥90,000 million, operating income of ¥9,300 million, ordinary income of ¥9,500 million and net income attributable to owners of the parent of ¥6,700 million or ¥99.43 per basic share. The company declared dividend of ¥13.00 per share for the year ended March 31, 2015 compared to ¥12.00 per share for the same period a year ago. The dividend is payable on June 29, 2015. The company provided dividend guidance for the second quarter and full year of year ending March 31, 2016. For the quarter, the company expects to pay dividend of ¥14.00 per share against ¥12.00 per share a year ago. For the year, the company expects to pay dividend of ¥14.00 per share against ¥13.00 per share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4516:JP ¥4,065.00 JPY +155.00

4516 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.137.70 CHF +0.90
United Therapeutics Corp $172.93 USD -1.02
View Industry Companies
 

Industry Analysis

4516

Industry Average

Valuation 4516 Industry Range
Price/Earnings 42.1x
Price/Sales 3.1x
Price/Book 2.5x
Price/Cash Flow 41.7x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NIPPON SHINYAKU CO LTD, please visit www.nippon-shinyaku.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.